HRTS - ETF AI Analysis
Top Page
Tema Cardiovascular and Metabolic ETF (HRTS)
Rating:66Neutral
Price Target:―
Positive Factors
Exposure to Leading Healthcare Companies
The ETF holds several well-known global healthcare leaders, which can provide stability and long-term growth potential.
Many Top Holdings Showing Solid Momentum
Several of the largest positions, such as AstraZeneca, Merck, Johnson & Johnson, Gilead, and Novartis, have shown strong recent performance, helping support the fund.
Focused Theme in Cardiovascular and Metabolic Health
The fund’s concentration in cardiovascular and metabolic healthcare targets a specific area of medical need that may benefit from ongoing innovation and demand.
Negative Factors
High Expense Ratio
The ETF charges a relatively high fee, which can eat into returns over time compared with lower-cost funds.
Recent Weak Overall Performance
The fund has delivered negative returns so far this year and over the last three months, indicating recent performance has been soft.
Concentration in U.S. Healthcare Stocks
With most assets in U.S. companies and almost all in the healthcare sector, the ETF is heavily exposed to one country and one industry, increasing sensitivity to sector-specific and regulatory risks.
HRTS vs. SPDR S&P 500 ETF (SPY)
AUM55.36M
RegionGlobal
Expense Ratio0.75%
Beta0.68
IssuerTema
Inception DateNov 21, 2023
Dividend Yield1.3%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,304
30 Day Avg. Volume5,123
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.57Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering44
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HRTS Summary
The Tema Cardiovascular and Metabolic ETF (HRTS) is a health care–focused fund that invests in companies working on treatments and technologies for heart disease, diabetes, and other metabolic conditions. It doesn’t track a traditional index, but instead follows this specific medical theme. Top holdings include well-known names like Eli Lilly and Johnson & Johnson. Someone might invest in HRTS to seek long-term growth from medical innovation and to get targeted exposure to leading drug and biotech companies. A key risk is that it is heavily concentrated in health care, so its value can swing with news and trends in this one sector.
How much will it cost me?The Tema Cardiovascular and Metabolic ETF (HRTS) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche within the health care sector.
What would affect this ETF?The HRTS ETF, focused on cardiovascular and metabolic health, could benefit from growing demand for innovative treatments as heart disease and diabetes remain global health priorities. Positive trends like advancements in biotech and pharmaceutical research, along with increased healthcare spending, may drive growth for its top holdings such as Eli Lilly and AstraZeneca. However, challenges like regulatory hurdles, patent expirations, or economic downturns affecting healthcare budgets could negatively impact the ETF's performance.
HRTS Top 10 Holdings
HRTS is heavily tilted toward big health care names, with Eli Lilly and UnitedHealth doing much of the heavy lifting as their shares keep rising on strong results and growth expectations. On the more speculative side, Revolution Medicines and Cytokinetics have been sprinting higher, adding extra fuel thanks to promising pipelines, though they also raise volatility. Offsetting some of that strength, Roche, AstraZeneca, and Thermo Fisher have been lagging, acting like a bit of a brake. Overall, it’s a globally diversified but tightly health-care-focused bet on cardiovascular and metabolic innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 11.74% | $6.50M | $1.12T | 49.88% | 72 Outperform | |
| UnitedHealth | 5.61% | $3.11M | $385.62B | 39.63% | 72 Outperform | |
| ― | 5.19% | $2.87M | ― | ― | ― | |
| Thermo Fisher | 4.06% | $2.25M | $195.86B | 21.20% | 72 Outperform | |
| Merck & Company | 3.91% | $2.17M | $305.12B | 48.20% | 80 Outperform | |
| Roche Holding | 3.89% | $2.15M | $329.57B | 28.18% | 74 Outperform | |
| Johnson & Johnson | 3.82% | $2.12M | $618.61B | 64.37% | 78 Outperform | |
| AstraZeneca | 3.57% | $1.97M | $265.85B | 22.81% | 80 Outperform | |
| Cytokinetics | 3.48% | $1.93M | $10.56B | 113.17% | 57 Neutral | |
| Revolution Medicines | 3.44% | $1.90M | $39.73B | 391.53% | 52 Neutral |
HRTS Technical Analysis
Positive
―
Price Trends
34.60
Positive
34.40
Positive
34.22
Positive
Market Momentum
0.74
Negative
58.00
Neutral
40.61
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HRTS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 35.75, equal to the 50-day MA of 34.60, and equal to the 200-day MA of 34.22, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 58.00 is Neutral, neither overbought nor oversold. The STOCH value of 40.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRTS.
HRTS Peer Comparison
Comparison Results
Performance Comparison
HRTS
Tema Cardiovascular and Metabolic ETF
36.40
8.31
29.58%
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents